Email this article Conjugates of Prostate-Specific Membrane Antigen Ligands with Antitumor Drugs
- Authors: Uspenskaya A.A.1, Machulkin A.É.1, Mazhuga A.G.1,2, Beloglazkina E.K.1
-
Affiliations:
- Department of Chemistry, M. V. Lomonosov Moscow State University
- D. Mendeleev University of Chemical Technology of Russia
- Issue: Vol 53, No 4 (2019)
- Pages: 288-297
- Section: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/245738
- DOI: https://doi.org/10.1007/s11094-019-01994-1
- ID: 245738
Cite item
Open Access
Access granted
Subscription Access
Abstract
Conjugates for targeted delivery that are based on low-molecular-mass prostate specific membrane antigen (PSMA) inhibitors are widely used and developed because of the deficiencies of existing methods for treating and diagnosing prostate cancer. The major classes of low-molecular-mass PSMA inhibitors, drug classes, and their mechanisms of action are discussed. Therapeutic conjugates for targeted delivery that are based on them are analyzed. Structural features of the linker that affect the biological activity and selectivity are identified.
Keywords
About the authors
A. A. Uspenskaya
Department of Chemistry, M. V. Lomonosov Moscow State University
Author for correspondence.
Email: uspenskaya.n@gmail.com
Russian Federation, GSP-1, Moscow, 199991
A. É. Machulkin
Department of Chemistry, M. V. Lomonosov Moscow State University
Email: uspenskaya.n@gmail.com
Russian Federation, GSP-1, Moscow, 199991
A. G. Mazhuga
Department of Chemistry, M. V. Lomonosov Moscow State University; D. Mendeleev University of Chemical Technology of Russia
Email: uspenskaya.n@gmail.com
Russian Federation, GSP-1, Moscow, 199991; Moscow, 125047
E. K. Beloglazkina
Department of Chemistry, M. V. Lomonosov Moscow State University
Email: uspenskaya.n@gmail.com
Russian Federation, GSP-1, Moscow, 199991
